Name: Yvonne Kalley Franklin | DOB: 6/17/1979 | MRN: U4772842 | PCP: Leilani D Paras, MD | Legal Name: Yvonne Kalley Franklin

PET CT MID BODY

Collected on Nov 16, 2026 1:21 PM

Results

Impression

History of metastatic breast cancer. Compared to prior PET MR July 21, 2026:
* The previously seen numerous foci of FDG uptake throughout the axial and appendicular skeleton are markedly decreased, with few areas of residual uptake. No new suspicious osseous lesions.
* Similar mild uptake in the left upper outer breast.
* Previously seen hypermetabolic right axillary lymph node is less conspicuous.

I have personally reviewed the images and agree with the report (or as edited).

Narrative

EXAMINATION:
PET CT MID BODY

CLINICAL INDICATION:
restaging.

Imaging requested for restaging.

Subsequent treatment strategy.

RADIOPHARMACEUTICAL:
FLUORODEOXYGLUCOSE F-18 FDG UWM UWM INJECTION,10.11 millicurie
Intravenous,11/16/2026 1224
Injection site: Left antecubital fossa

TECHNIQUE:
Extent: Skull vertex to toes.
Uptake time: 60 minutes.
Fasting blood glucose level prior to FDG injection: 94 mg/dL.

After radiopharmaceutical injection, nondiagnostic, noncontrast, nonbreathhold CT images were obtained for attenuation correction and fusion with emission PET images for anatomical localization.

Images were interpreted on Visage PACS.

COMPARISON:
PET/MR July 21, 2026, MRI CTL spine November 8, 2026

FINDINGS:
Mediastinal blood pool mean SUV: 1.3
Mediastinal blood pool maximum SUV: 1.4
Liver mean SUV: 2.1.

Head and neck:
Unremarkable.

Chest:
* Similar mild uptake involving the left upper outer breast with SUV max 2.0 (12/167), previously SUV max 1.9.
* Previously seen hypermetabolic right axillary lymph node is less conspicuous.

Abdomen and Pelvis:
Unremarkable.

Osseous structures:
The previously seen numerous foci of FDG uptake throughout the axial and appendicular skeleton are markedly decreased, with few areas of residual uptake, for example:
* Decreased uptake at the left posterior ninth rib pathologic fracture with underlying lesion with SUV max 1.6 (12/206), previously SUV max 3 5.
* Decreased uptake at left proximal femur lytic lesion with SUV max 4.2 (12/401), previously SUV max 5.4.
* Similar uptake in the right femoral neck lytic lesion with SUV max 6.8 (12/392), previously SUV max 6.5.
* Decreased uptake in the right L5 vertebral body lytic lesion with SUV max 2.1 (12/305), previously with SUV max 5.4.

Extremities:
Unremarkable.

Additional noncontrast CT findings:
Please see separately dictated report for same-day contrast CT. No additional findings are identified on the non-contrast CT performed for attenuation correction.

Ordering provider: Lynn Symonds
Reading physician: Hubert Vesselle
Study date: Nov 16, 2026 12:24 PM
Collection date: Nov 16, 2026 1:21 PM
Result date: Nov 17, 2026 6:02 PM
Result status: Final

MyChart® licensed from Epic Systems Corporation© 1999 - 2026